In an increasingly tense geopolitical context, the European Union aims to secure the health sector as well, proposing new regulations to improve the availability of essential medicines for European health systems.
The goal is to have a tool similar to the Critical Raw Material Act, capable of increasing the production of critical medicines within European borders to reduce dependencies on foreign countries, also by strengthening supply chains - subjected to increasing global competition - through supplier diversification.
To achieve this, the Critical Medicines Act (CMA) provides for interventions in various fields. On one hand, it aims to ensure greater and specific support for investment projects in the production of critical medicines in Europe, introducing the definition of “Strategic Projects”: investments that will benefit from favorable conditions (financial and regulatory) for their realization.
